Search

Author/Creator Gilles, L.

1. FRI0344 THE LONG-TERM EFFECT OF TREATING PSORIATIC ARTHRITIS WITH THE JANUS KINASE 1-SELECTIVE INHIBITOR FILGOTINIB ON LIPID PROFILES: AN ANALYSIS OF THE EQUATOR AND EQUATOR2 TRIALS. (2nd June 2020)

Authors:
Husni, M. E.; Gladman, D. D.; Helliwell, P.; Van den Bosch, F.; Tasset, C.; Meuleners, L.; Gilles, L.; Gheyle, L.; Trivedi, M.; Alani, M.; Besuyen, R.; Mease, P. J.
Journal:
Annals of the rheumatic diseases
Issue:
Volume 79(2020)Supplement 1
Page Start:
766
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. FRI0339 LONG-TERM EFFICACY OF THE ORAL SELECTIVE JANUS KINASE 1 INHIBITOR FILGOTINIB IN PSORIATIC ARTHRITIS: WEEK 52 RESPONSE PATTERNS IN INDIVIDUAL PATIENTS FROM AN OPEN-LABEL EXTENSION (OLE) STUDY (EQUATOR2). (2nd June 2020)

Authors:
Gladman, D. D.; Coates, L. C.; Van den Bosch, F.; Helliwell, P.; Tasset, C.; Meuleners, L.; Gilles, L.; Gheyle, L.; Trivedi, M.; Alani, M.; Besuyen, R.; Mease, P. J.
Journal:
Annals of the rheumatic diseases
Issue:
Volume 79(2020)Supplement 1
Page Start:
763
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. THU0377 IMPACT OF FILGOTINIB ON STRUCTURAL LESIONS IN THE SACROILIAC JOINTS AT 12 WEEKS IN PATIENTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS: MAGNETIC RESONANCE IMAGING DATA FROM THE DOUBLE-BLIND, RANDOMIZED TORTUGA TRIAL. (2nd June 2020)

Authors:
Maksymowych, W. P.; Ǿstergaard, M.; Landewé, R. B. M.; Barchuk, W.; Liu, K.; Tasset, C.; Gilles, L.; Hendrikx, T.; Besuyen, R.; Baraliakos, X.
Journal:
Annals of the rheumatic diseases
Issue:
Volume 79(2020)Supplement 1
Page Start:
421
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. FRI0343 EFFICACY AND SAFETY OF FILGOTINIB, A SELECTIVE JANUS KINASE 1 INHIBITOR, IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: SUBGROUP ANALYSES FROM A RANDOMIZED, PLACEBO-CONTROLLED, PHASE 2 TRIAL (EQUATOR). (2nd June 2020)

Authors:
Helliwell, P.; Van den Bosch, F.; Coates, L. C.; Gladman, D. D.; Tasset, C.; Meuleners, L.; Gilles, L.; Gheyle, L.; Trivedi, M.; Alani, M.; Besuyen, R.; Mease, P. J.
Journal:
Annals of the rheumatic diseases
Issue:
Volume 79(2020)Supplement 1
Page Start:
765
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. Simeprevir added to peginterferon and ribavirin lessens time with fatigue, depressive symptoms and functional limitations in patients with chronic hepatitis C compared with peginterferon and ribavirin: results from 1161 patients in the QUEST‐1, QUEST‐2 and PROMISE studies. Issue 8 (9th December 2014)

Authors:
Scott, J.; Gilles, L.; Fu, M.; Brohan, E.; Panter, C.; Arbuckle, R.; Jessner, W.; Beumont, M.
Journal:
Journal of viral hepatitis
Issue:
Volume 22:Issue 8(2015)
Page Start:
639
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

9. PFAS levels and exposure determinants in sensitive population groups. (February 2023)

Authors:
Fábelová, L.; Beneito, A.; Casas, M.; Colles, A.; Dalsager, L.; Den Hond, E.; Dereumeaux, C.; Ferguson, K.; Gilles, L.; Govarts, E.; Irizar, A.; Lopez Espinosa, M.J.; Montazeri, P.; Morrens, B.; Patayová, H.; Rausová, K.; Richterová, D.; Rodriguez Martin, L.; Santa-Marina, L.; Schettgen, T.
Journal:
Chemosphere
Issue:
Volume 313(2023)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗